AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00275561
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhaler swallowed twice a day for 6 weeks
Trial: NCT00193011
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide
Trial: NCT00193011
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate
Trial: NCT02520635
Drug: supra-early TEMODAL® chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02520635
Drug: standard TEMODAL® chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03203811
Drug: HTI-2088
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 dose levels
Trial: NCT03203811
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo oral tablet
Trial: NCT02294344
Drug: CTX
RxNorm normalized name: CTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First,patients received methylprednisolone pulse therapy followed by oral prednisone and intravenous cyclophosphamide (IV-CTX) pulse therapy.~After three months therapy, if the renal function was not recover, the patient would be withdrawn from the study. The other patients after CTX pulse therapy for 6 months and achieve remission to receive oral maintenance therapy with azathioprine (AZA).~The dosage of AZA was 1.0-2.0mg/kg/d(more than 50mg/d) and adjusted by white cell count and liver enzyme. If white cell count \<3×109/L or an increase in liver enzyme to more than twice the normal upper limit, the dosage of AZA should be reduced. If white cell count \<3×109/L or liver enzyme increased repeatedly, the patient would be withdrawn from the study.
Trial: NCT03642717
Drug: JARDIANCE DUO®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: empagliflozin and metformin
Trial: NCT02609334
Drug: CRD007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single dose given 3 hours prior to Mannitol challenge
Trial: NCT00665977
Drug: Thermosmart & placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a Fisher \& Paykel 604 CPAP machine with Thermosmart™ heated humidity set at their prescribed pressure. Subjects will also be given nasal steroid placebo (purified water) and instructed to deliver two sprays in each nostril daily
Trial: NCT00665977
Drug: Placebo Device & Nasacort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visit 3 will be identical to visit 2, with the exception being the crossover of double-blind treatment. Subjects will now receive the Fisher \& Paykel 604 CPAP machine with traditional heated humidity and a deactivated Thermosmart™ tube set to their prescribed pressure. Subjects will also be given the nasal steroid Nasacort AQ (triamcinolone acetonide) at a dosage of 220 mcg. They will be instructed to deliver two sprays in each nostril daily. Once again, phone follow-up will be made 7-10 days after the visit to assess compliance with study procedures and adverse events.
Trial: NCT00648596
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet by mouth 1 hour before sexual activity for 12 weeks
Trial: NCT03394781
Drug: DUR-928
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral suspension daily for 28 days
Trial: NCT02297815
Drug: Broad-spectrum antibiotics
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate, azithromycin, cefdinir, cefprozil, cefuroxime axetil, cefadroxil, cephalexin
Trial: NCT02297815
Drug: Narrow-spectrum antibiotics
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin, Penicillin
Trial: NCT00699556
Drug: placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline combined with capsaicin to mimic the brief nasal irritation from active nicotine spray The placebo nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital.
Trial: NCT02299557
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel applied intra-anally once daily
Trial: NCT01144624
Drug: AZD9773
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single loading dose followed by 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
Trial: NCT01144624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of a saline solution
Trial: NCT01434901
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo will be taken by mouth 1 hour before ingestion of a mixed meal.
Trial: NCT00575055
Drug: Placebo Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given by infusion every 13 weeks for a total of 6 infusions.
Trial: NCT03333928
Drug: HTD1801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTD1801 tablets, 250 mg
Trial: NCT03333928
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets manufactured to mimic HTD1801 tablets
Trial: NCT01282255
Drug: NNC109-0012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will receive 12 weekly doses of 3 mg/kg of NNC109-0012 administered subcutaneously (under the skin)
Trial: NCT01282255
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will receive 12 weekly doses of 3 mg/kg of Placebo administered subcutaneously (under the skin)
Trial: NCT01384565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
Trial: NCT02205190
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02205190
Drug: Fimasartan/Rosuvastatin combination
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03650413
Drug: UTTR1147A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UTTR1147A will be administered based on disease status, as described in the protocol.
Trial: NCT04136548
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive 75 ug Fentanyl while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
Trial: NCT02220244
Drug: MD1003 100mg capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03272477
Drug: Perjeta Injectable Product
RxNorm normalized name: Perjeta Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 840mg (loading dose) day1 cycle 1, 420mg at day1 of each subsequent cycle, every 3 weeks. (The latter cycle is called cycle of treatment and is to be given 4 times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
Trial: NCT01579058
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for 4 years
Trial: NCT01709110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide arm placebo administered orally.~Risedronate arm placebo administered SC.
Trial: NCT01709110
Drug: Calcium
RxNorm normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01475643
Drug: Prednisolones acetate
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.
Trial: NCT03770208
Drug: Control: Standard Care + Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV bolus and infusion. Weight based to mimic lidocaine volume.
Trial: NCT04227275
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-PSMA-TGFβRDN genetically modified T cells
Trial: NCT02105610
Drug: total intravenous anesthetics
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03632187
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous placebo every week during 3 months
Trial: NCT00049439
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral cyclophosphamide on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
Trial: NCT04014257
Drug: NOV1601(CHC2014)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a highly selective pan-TRK(tropomyosin receptor kinase) inhibitor targeting tropomyosin receptor kinase A (TRKA), tropomyosin receptor kinase B(TRKB), and tropomyosin receptor kinase C(TRKC)
Trial: NCT03391830
Drug: Atorvastatin-Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg
Trial: NCT03391830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00903617
Drug: GSK256073
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg for 8 weeks
Trial: NCT00903617
Drug: GSK256073
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg for 8 weeks
Trial: NCT00903617
Drug: GSK256073
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg for 8 weeks
Trial: NCT00903617
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for 8 weeks
Trial: NCT00903617
Drug: GSK256073
FDA approved: no
EMA approved: no
PMDA approved: no
Description: x mg for 8 weeks based from data from Part A
Trial: NCT00903617
Drug: GSK256073
FDA approved: no
EMA approved: no
PMDA approved: no
Description: optional dose based on data from Part A
Trial: NCT03752307
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical microcrystalline cellulose placebo manufactured to mimic Isoxsuprine Hydrochloride 10 MG capsules
Trial: NCT03752307
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This can be any accepted regimen, including daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon
Trial: NCT02120781
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to placebo will receive injections of sterile saline into the vocal fold(s).
Trial: NCT00485758
Drug: Comparator : placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER niacin/laropiprant Placebo
Trial: NCT03198091
Drug: Dun Ye Guan Xin Ning
RxNorm normalized name: Scrophularia ningpoensis root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dun Ye Guan Xin Ning tablet 320 mg orally every time and 3 times per day for 6 months.
Trial: NCT02676674
Drug: Dose 1
RxNorm normalized name: Aldose 1-epimerase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with vitamin D deficiency will be given 100,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
Trial: NCT02676674
Drug: Dose 2
RxNorm normalized name: Fluzone High-Dose 2011-2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with vitamin D deficiency will be given 300,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
Trial: NCT04283955
Drug: High-dose MTX based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received MTX therapy at the dose of 5g/m2 for 24 hours. Each dose of HD-MTX therapy was followed by 6\~7 times of leucovorin rescue 12 hours after the end of MTX infusion, at the dose of 15 mg/ m2 every 6 hours. The plasma MTX levels were monitored at 0, 24, 48, 72 hours from the initiation of HD-MTX infusion. To maintain the urine pH at approximately 7\~8, intravenous hydration and alkalization at the dose of 1,500ml/ m2 per day were achieved 12 hours prior to the initiation of HD-MTX administration (D0) and 3,000ml/ m2 per day lasted for the following 3 days (D1 to D3). CF was used to rinse mouth to prevent oral mucositis from D1 to D3. We closely monitored the volume and pH of the urine via routine test from D0 to D4.
Trial: NCT03367403
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT03367403
Drug: LY3202626
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01243008
Drug: Application of SHB001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Cohort 1: Application of SHB001 on the skin of right thigh~* Cohort 2:~  1. Application of SHB001 on the skin of right thigh~ 2. punch biopsies of treated skin areas
Trial: NCT02934841
Drug: sham
RxNorm normalized name: SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01377909
Drug: statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily statin orally for 48 weeks
Trial: NCT00985608
Drug: Group A: NCA 600 mg+antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics
Trial: NCT00985608
Drug: Group B: antibiotic treatment (control)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics
Trial: NCT01822899
Drug: Placebo ACCUHALER/DISKUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry white powder of matching placebo as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
Trial: NCT01822899
Drug: Placebo NDPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry white powder of matching placebo as NDPI with 30 doses (2 strips with 30 blisters per strip).
Trial: NCT01268046
Drug: Estradiol oral capsule
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 oral capsule (1 mg estradiol) administered daily for one month
Trial: NCT01268046
Drug: trasdermal placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transdermal placebo patch with patch change every 84 hr for one month
Trial: NCT01268046
Drug: placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo oral capsule administered daily for one month.
Trial: NCT01574820
Drug: placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet for 6 months
Trial: NCT00005987
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02206425
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
Trial: NCT02206425
Drug: PLD
RxNorm normalized name: PLD1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
Trial: NCT02229825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT04220372
Drug: Tongxinluo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provided by Shijiazhuang Yiling Pharmaceutical CO., LTD
Trial: NCT04220372
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provided by Shijiazhuang Yiling Pharmaceutical CO., LTD
Trial: NCT00758069
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, QD, taken orally for 4 weeks
Trial: NCT00740441
Drug: AS1411
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS1411 40 mg/kg/day) will be administered on days 1-4 via a continuous iv infusion every 28-day cycle for up to 2 cycles
Trial: NCT03726658
Drug: AGN-241751
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-241751 is supplied in tablet form
Trial: NCT03726658
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is supplied in tablet form
Trial: NCT00635349
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meloxicam 7.5 mg or 15 mg per day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and meloxicam 7.5 mg or 15 mg per day from Day 29 to Day 85.
Trial: NCT00635349
Drug: Tramadol Hydrochloride Plus Acetaminophen
RxNorm normalized name: acetaminophen / tramadol hydrochloride Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with NSAIDs (meloxicam \[7.5 mg or 15 mg once daily\] or aceclofenac \[100 mg twice daily\]) from Day 1 to Day 28, and fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
Trial: NCT02579421
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00158249
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched for physical appearance
Trial: NCT03283202
Drug: Cyclophosphamide 750mg/m2 by IV infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
Trial: NCT01670279
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02318368
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00110435
Drug: MK0653A, ezetimibe (+) simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00110435
Drug: Duration of Treatment: 4 wk placebo run in then 6 wk active
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01667497
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01864148
Drug: BIIB033
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00442494
Drug: intravenous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02078024
Drug: IVM plus ALB
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01232920
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All methotrexate doses will be taken orally once per week in a divided dose (half in the morning, half in the evening), and should be taken with food. For the first two weeks, a loading dose of 15 mg/week orally will be administered to assess tolerability. After two weeks, the dose will be ramped up to 25 mg/week until the end of follow-up or until treatment failure due to intolerability, adverse events, or of lack of efficacy. If the study ophthalmologist decides to reduce the study treatment dose due to intolerability, the dose will be reduced to 20 mg per week while maintaining masking. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 15 mg per week.
Trial: NCT02066792
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill
Trial: NCT01170494
Drug: ergocal1000 IU & cholecal 1000 IU orally daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ergocalciferol 1000 IU and cholecalciferol 1000 IU orally every day
Trial: NCT01170494
Drug: placebo orally everyday
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo orally everyday
Trial: NCT02443142
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 800 mg orally three times per day for two days for study subjects who are randomized to the ibuprofen arm.
Trial: NCT02443142
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1000 mg orrally three times per day for two days for subjects who are randomized to the acetaminophen arm.
Trial: NCT03002012
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo tablet
Trial: NCT01301287
Drug: Chlorella
RxNorm normalized name: Chlorella
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02182362
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00356772
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00885066
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00177970
Drug: intravenous immunoglobulin G (IVIG)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG to be given IV to patients with C-Diff .
Trial: NCT00177970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to be given IV to patients with C-Diff
Trial: NCT01928862
Drug: Prepopik® ½ Sachet x 2 (9-12 years)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01928862
Drug: Prepopik® 1 Sachet x 2 (9-12 years)
FDA approved: no
EMA approved: no
PMDA approved: no